May 1, 2026: Case Count Climb to Over 3,600 in MDL Involving Trulicity and Other GLP-1 Drugs A total of 3,636 gastrointestinal-related lawsuits have been consolidated into the MDL against Eli Lilly (Trulicity) and other companies
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al
(NASDAQ: ALT) announced that pemvidutide received FDA Breakthrough Therapy designation for the treatment of MASH, further advancing development of the companys GLP-1/glucagon dual receptor agonist platform
"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1"
Blood Sugar Management Liraglutide, the active ingredient in Saxenda, stimulates insulin release from the pancreas
Correlation Between Gender and Spontaneous C-Cell Tumors in the Thyroid Gland of the Wistar Rat